Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Adverse drug reactions (ADRs) represent a major public health and economic global problem. Growing evidence suggests that pharmacogenomics may potentially play a role in reducing drug-induced adverse events. Research efforts are increasingly directed towards this goal. However, knowledge about whether or not pharmacogenomics may be useful as a novel approach in postmarketing surveillance programs is at present rather limited. A critical analysis of some of the methodological design and ethical issues generated by the potential incorporation of pharmacogenomic profiling into pharmacosurveillance programs is presented.
Issa
Amalia M
AM
UCLA School of Public Health, Room 31-245A CHS, Campus Box 951772, Los Angeles, CA 90095-1772, USA. aissa1@ucla.edu
D016907:Adverse Drug Reaction Reporting Systems / Q000941:ethics / Q000592:standards / Q000639:trends*; D064420:Drug-Related Side Effects and Adverse Reactions; D005544:Forecasting; D010597:Pharmacogenetics / Q000941:ethics; D011358:Product Surveillance, Postmarketing / Q000592:standards / Q000639:trends*